ClinicalTrials.Veeva

Menu

Mesenchymal Stem Cells Derived Exosomes in Osteoarthritis Patients

I

Isfahan University of Medical Sciences

Status

Enrolling

Conditions

Osteoarthritis, Knee

Treatments

Biological: Exosome

Study type

Interventional

Funder types

Other

Identifiers

NCT06466850
Isfahan med

Details and patient eligibility

About

Present research focuses on the potential of exosomes, which are small vesicles secreted by mesenchymal stem cells (MSCs), as a therapeutic approach for osteoarthritis (OA).

OA is a degenerative joint disorder characterized by the destruction of cartilage and loss of extracellular matrix. It's associated with pro-inflammatory cytokines and increased expression of matrix metalloproteinase (MMP) and "a disintegrin and metalloproteinase with thrombospondin motifs" (ADAMTS).

MSCs have been explored as a new treatment for OA over the last decade1. It's suggested that the paracrine secretion of trophic factors, in which exosomes play a crucial role, contributes to the mechanism of MSC-based treatment of OA.

Exosomes derived from MSCs may suppress OA development. They carry bioactive molecules of the parental cells, including non-coding RNAs (ncRNAs) and proteins and anti-inflammatory factors. These exosomes have shown a significant impact on the modulation of various physiological behaviors of cells in the joint cavity.

This research provides hope for developing more effective and predictable methods of using MSC-derived exosomes for OA treatment.

Enrollment

20 estimated patients

Sex

All

Ages

45 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Chronic history (for at least 3 months) of knee joint pain
  • Body mass index (BMI) between 21.5 and 29.5
  • Radiographically documented knee osteoarthritis of grades 1 to 3 (Kellgren-Lawrence (K-L) radiographic classification scale)

Exclusion criteria

  • Rheumatoid arthritis and other rheumatic diseases
  • Varus or valgus more than 10 degrees; lateral subluxation of the patella
  • Deformity at the joint levels or adjacent to the knee due to fracture or any other injury
  • Complete rupture of the ligament and meniscus leading to laxity or locking
  • Serious systemic, oncohematological, autoimmune diseases; history of severe allergy; serious failure of vital organs, inability to walk
  • Hyaluronic acid infiltration within the previous six months
  • Hemoglobin levels <10 g/dL;

Trial design

Primary purpose

Supportive Care

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

20 participants in 1 patient group

Treatment
Experimental group
Description:
Patients with moderate to severe osteoarthritis, Kellgren-Lawrence grade 2,3 in both knees; accompanied by mild to moderate pain and swelling are included.
Treatment:
Biological: Exosome

Trial contacts and locations

1

Loading...

Central trial contact

Masoud Soleimani, Prof; Leila Dehghani, Dr

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems